

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

Information for the public

Published: 26 July 2017

www.nice.org.uk

Nivolumab (Opdivo) is available on the NHS. It is a possible treatment for relapsed or refractory classical Hodgkin lymphoma in adults who have already had both brentuximab vedotin and a stem cell transplant using their own cells.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Lymphoma Association](#), 0808 808 5555
- [Bloodwise](#) (previously Leukaemia & Lymphoma Research), 0808 2080 888
- [Leukaemia CARE](#), 08088 010 444
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040
- [CLL Support Association](#), 0800 977 4396

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2612-1